From: Successful treatment of thyrotoxicosis is accompanied by a decrease in serum sclerostin levels
Mean | Median | SD | Min | Max | p-value | |
---|---|---|---|---|---|---|
anti-TPO – before [IU/ml] | 222.7 | 21.8 | 356.0 | 5 | 1000 | - |
anti-Tg – before [IU/ml] | 109.2 | 20.2 | 222.7 | 10 | 803 | - |
anti-TSHR – before [IU/l] | 7.6 | 1.3 | 11.6 | 0.3 | 40.0 | 0.999 |
anti-TSHR – after [IU/l] | 11.9 | 10.9 | 5.9 | 6.6 | 18.3 | |
TSH - before [mIU/l] | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.013 |
TSH – after [mIU/l] | 1.1 | 0.0 | 1.7 | 0.0 | 5.8 | |
FT3 – before [pg/ml] | 8.74 | 7.53 | 4.79 | 4.02 | 16.5 | 0.0010 |
FT3 – after [pg/ml] | 3.49 | 3.54 | 2.40 | 0.74 | 4.8 | |
FT4 – before [ng/ml] | 4.48 | 2.21 | 1.01 | 7.84 | 32.5 | 0.0010 |
FT4 – after [ng/ml] | 1.02 | 1.07 | 0.44 | 0.34 | 1.7 | |
Sclerostin- before [pmol/l] | 55.46 | 41.90 | 20.90 | 39.29 | 148.8 | 0.0015 |
Sclerostin – after [pmol/l] | 35.73 | 27.20 | 15.70 | 23.46 | 99.6 |